HCM
PCRX icon

Highbridge Capital Management’s Pacira BioSciences PCRX Stock Holding History

Highbridge Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-11,400
Closed -$469K – 1725
2015
Q3 		$469K Buy
+11,400
New +$698K 0.01% 1049

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Highbridge Capital Management's PCRX Position: Q2 2018 in Review

Highbridge Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2018, closing a stake of 50,000 shares — an estimated $1.56M sold.

Highbridge Capital Management first reported a position in PCRX in Q3 2015 and held it in 7 quarters. The position peaked at $9.26M in Q2 2017. 156 funds tracked by Wall St. Rank hold PCRX as of Q2 2018.

  • Highbridge Capital Management reported no remaining Pacira BioSciences position as of Q2 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 50,000 Pacira BioSciences shares in Q2 2018, an estimated $1.56M.
  • Highbridge Capital Management first reported a position in Pacira BioSciences in Q3 2015 and held it in 7 quarters.
  • Highbridge Capital Management's Pacira BioSciences position peaked at $9.26M in Q2 2017.
  • 156 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.